Spots Global Cancer Trial Database for A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Official Title: A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies
Study ID: NCT03652077
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Angeles Clinical and Research Institute, Los Angeles, California, United States
University of Mississippi, Jackson, Mississippi, United States
Hackensack Medical Center, Hackensack, New Jersey, United States
Carolina BioOncology, Huntsville, North Carolina, United States
Contact Details
Name: Nawel Bourayou, MD
Affiliation: Incyte Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
